Figure 1
Figure 2
Figure 3
Patients’ characteristics
| Patients characteristics | No patients | % |
|---|---|---|
| 129 | 100 | |
| Age (years) | ||
| Median | 56 | |
| Q1-Q3 | 48-64 | |
| Histology | ||
| IDC | 104 | 80.7 |
| ILC | 25 | 19.3 |
| Tumour size | ||
| T1 | 29 | 9.3 |
| T2 | 79 | 45.7 |
| T3 | 21 | 45.0 |
| Histological grade | ||
| G1 | 12 | 9.3 |
| G2 | 59 | 45.7 |
| G3 | 58 | 45.0 |
| Lymphovascular invasion | ||
| Yes | 54 | 41.9 |
| No | 64 | 49.6 |
| N/A | 11 | 8.5 |
| Perineural invasion | ||
| Yes | 20 | 15.5 |
| No | 83 | 64.3 |
| N/A | 26 | 20.2 |
| No. of positive axillary lymph nodes (PALN) | ||
| 1-3 | 29 | 22.5 |
| 4-15 | 70 | 54.3 |
| >15 | 30 | 23.2 |
| No. of PALN according to N category | ||
| N1 | 29 | 22.5 |
| N2 | 47 | 36.5 |
| N3 | 53 | 41.0 |
| Estrogen receptor | ||
| Positive | 100 | 77.5 |
| Negative | 29 | 22.5 |
| Progesteron receptor | ||
| Positive | 85 | 65.9 |
| Negative | 44 | 34.1 |
| HER-2 overexpression | ||
| Positive | 37 | 28.7 |
| Negative | 92 | 71.3 |
| Adjuvant hormone therapy | ||
| Yes | 101 | 78.3 |
| No | 28 | 21.7 |
| Adjuvant chemotherapy | ||
| Yes | 108 | 83.7 |
| No | 21 | 16.3 |
| Adjuvant chemotherapy with anthracycline: | ||
| Yes | 99 | 76.7 |
| No | 30 | 23.2 |
| Breast cancer subtype | ||
| Luminal A | 61 | 47.3 |
| Luminal B | 40 | 31.0 |
| Her2-overexpression | 12 | 12.4 |
| Triple negative breast cancer (TNBC) | 16 | 9.3 |